Page 2 - Nasdaq Fdmt News Today

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,909 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total value of $57,270.00. Following the sale, the insider now owns 1,737 shares in the company, valued at […]

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Equities research analysts at Leerink Partnrs raised their Q4 2023 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research note issued to investors on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.39) per […]

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) traded up 9.4% during mid-day trading on Friday . The company traded as high as $29.53 and last traded at $29.43. 779,157 shares traded hands during trading, a decline of 50% from the average session volume of 1,558,401 shares. The stock had previously closed […]

EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday after BMO Capital Markets raised their price target on the stock from $50.00 to $70.00. BMO Capital Markets currently has an outperform rating on the stock. 4D Molecular Therapeutics traded as high as $30.40 and […]

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...

Privium Fund Management B.V. purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the 3rd quarter, HoldingsChannel reports. The fund purchased 33,680 shares of the company’s stock, valued at approximately $429,000. Other hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC […]

Privium Fund Management B.V. acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 33,680 shares of the company’s stock, valued at approximately $429,000. Privium Fund Management B.V. owned 0.08% of 4D […]

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average […]